Aquestive Therapeutics, INC Form 4 insider transactions

Carl N. Kraus, Chief Medical Officer of Aquestive Therapeutics, reports disposition of shares to cover tax obligations related to vesting Restricted Stock Units.

Director Timothy E. Morris of Aquestive Therapeutics, Inc. acquired 38,000 stock options on June 20, 2024, exercisable for common stock.

Director Marco Taglietti acquired stock options for 38,000 shares of Aquestive Therapeutics common stock on June 20, 2024.

Director Gregory B Brown acquired 38,000 stock options in Aquestive Therapeutics, Inc.

Director Julie Krop acquired stock options for 38,000 shares of Aquestive Therapeutics common stock on June 20, 2024.

Director John Cochran of Aquestive Therapeutics acquired 38,000 stock options on June 20, 2024, according to a Form 4 filing.

Director Santo J. Costa acquired 38,000 stock options in Aquestive Therapeutics, Inc. on June 20, 2024.

Sherry Korczynski, SVP of Sales and Marketing at Aquestive Therapeutics, acquired 25,000 shares of restricted common stock on June 7, 2024, which will vest in three annual installments.

Stephen Wargacki, Chief Science Officer of Aquestive Therapeutics, acquired 10,000 shares of restricted common stock on May 10, 2024, which will vest in three annual installments.

Director Abigail L. Jenkins acquired 57,000 non-qualified stock options in Aquestive Therapeutics, Inc. on May 10, 2024.

Alexander Mark Schobel, Chief Innovation/Tech Officer of Aquestive Therapeutics, sold 50,000 shares of common stock on March 15, 2024, according to a recent SEC filing.

Daniel Barber, CEO of Aquestive Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations related to vested Restricted Stock Units.

Peter E. Boyd, an executive at Aquestive Therapeutics, disposed of 8,370 shares to cover tax obligations related to vesting Restricted Stock Units.

Lori Braender, SVP and General Counsel of Aquestive Therapeutics, reports the disposal of shares to cover tax obligations related to vesting Restricted Stock Units.

A. Ernest Toth Jr., SVP and Chief Financial Officer of Aquestive Therapeutics, Inc., reports the withholding of 11,705 common stock shares to cover tax obligations related to vesting Restricted Stock Units on March 9, 2024.

Stephen Wargacki, SVP of Research & Development at Aquestive Therapeutics, reports disposing of shares to cover tax obligations related to vesting Restricted Stock Units.

Cassie Jung, SVP of Operations at Aquestive Therapeutics, reports disposition of shares to cover tax obligations related to vesting Restricted Stock Units.

Alexander Mark Schobel, Chief Innovation/Tech Officer of Aquestive Therapeutics, sold 25,000 shares of common stock on March 8, 2024, under a pre-arranged 10b5-1 trading plan.

Lori J. Braender, SVP, General Counsel of Aquestive Therapeutics, reports acquiring 135,000 shares of common stock and disposing of an unspecified amount, while also being granted options to purchase 67,500 shares.

A. Ernest Toth Jr., CFO of Aquestive Therapeutics, reports acquisition of 120,000 shares of common stock and 60,000 non-qualified stock options, along with the disposition of 260,000 shares.

Alexander Schobel, Chief Innovation/Tech Officer of Aquestive Therapeutics, reports the acquisition of 82,500 shares of restricted common stock and 41,250 non-qualified stock options.

Carl N. Kraus, Chief Medical Officer of Aquestive Therapeutics, acquired 112,500 shares of common stock and options to purchase 56,250 shares on March 7, 2024.

Daniel Barber, CEO of Aquestive Therapeutics, acquired common stock and stock options on March 7, 2024, as reported in a Form 4 filing with the SEC.

Cassie Jung, SVP of Operations at Aquestive Therapeutics, reports acquisition and disposal of company stock and derivative securities.

Peter E. Boyd, an executive at Aquestive Therapeutics, reported the acquisition of restricted stock and stock options, along with a correction to a previous filing regarding shares beneficially owned.

Stephen Wargacki, SVP of Research & Development at Aquestive Therapeutics, reports acquisition and disposal of common stock and derivative securities.